HCPCS code J9264: Paclitaxel protein-bound billing guide

Key Takeaways

HCPCS code J9264 describes injection, paclitaxel protein-bound particles (Abraxane/nab-paclitaxel), billed at 1 mg = 1 service unit.

Effective January 1, 2025, J9264 replaced its discontinued predecessor code as the designated billing code for this drug.

J9264 is subject to CMS JW and JZ modifier requirements; wastage must be reported correctly to avoid audit risk.

Practice management software like Pabau helps oncology billing teams track drug units, apply modifiers, and document chemotherapy encounters accurately with built-in claims management tools.

HCPCS code J9264 is the Healthcare Common Procedure Coding System Level II code for injection, paclitaxel protein-bound particles, 1 mg, better known by its brand name Abraxane. Oncology and infusion billing teams use it to report nab-paclitaxel chemotherapy, and every claim line depends on getting the unit count, modifier, and NDC right.

This guide covers the code descriptor, billing units, JW/JZ modifier rules, coverage, the January 2025 code change, NDC crosswalk, documentation requirements, and how J9264 is paid across different billing settings.

HCPCS code J9264: Code description and clinical overview

The official descriptor for HCPCS code J9264 is “Injection, paclitaxel protein-bound particles, 1 mg.” It is the J code for Abraxane (nab-paclitaxel), the albumin-bound formulation of paclitaxel given by intravenous infusion. Because Abraxane is a brand of nab-paclitaxel, the J code for paclitaxel protein-bound is this same J9264, billed at 1 mg per service unit.

One point trips up coders searching for a “J9264 CPT code” or an “Abraxane CPT code”: J9264 is a HCPCS Level II code, not a CPT code. Paclitaxel protein-bound has no CPT code of its own.

The drug is reported with J9264, while the infusion is billed separately with CPT administration codes such as 96413 and 96415. So the J9264 CPT code description you are looking for is really the HCPCS descriptor above.

Every claim carrying this code demands precise unit tracking and modifier compliance, making it a key focus for claims management software.

Paclitaxel protein-bound belongs to the antimitotic agent drug class, taxane subclass. Patients receive it intravenously, not orally. The drug is classified under the HCPCS J-code series (J9000-J9999), which covers chemotherapy drugs and related injectable medications billed under Medicare Part B’s buy-and-bill model.

Important distinction: conventional paclitaxel (Taxol) and nab-paclitaxel (Abraxane) are different formulations. The FDA approved conventional paclitaxel in 1992, but Abraxane received its own separate FDA approval in January 2005. Do not reference 1992 as Abraxane’s approval date; that applies to its conventional predecessor.

Billing units and dosage calculation for J9264

The unit of service for HCPCS code J9264 is straightforward: 1 mg equals 1 billing unit. If a patient receives 100 mg of paclitaxel protein-bound, you bill 100 units of J9264.

Abraxane comes in 100 mg vials. Clinicians calculate dosing on a weight-based scale, typically in mg/m² of body surface area. This means actual administered doses vary by patient, and leftover drug in a vial is common. That leftover quantity has billing implications under the JW and JZ modifier rules described in the next section.

Per the CMS HCPCS overview, CMS maintains J-codes and updates them annually. Billing teams should verify the current year’s code file before each plan year begins.

January 2025 code change: What replaced what

Effective January 1, 2025, a predecessor HCPCS code used for paclitaxel protein-bound particles was discontinued. J9264 is now the sole designated code for this drug under current CMS billing policy. According to American Regent’s billing and coding guide, payers will not accept claims submitted with the discontinued code after December 31, 2024.

Practices still using billing templates built before 2025 should audit their charge master entries. Any claim submitted with the old code for dates of service on or after January 1, 2025 will likely deny. Update your code references now if you have not already done so.

JW and JZ modifiers for HCPCS code J9264

CMS lists J9264 in its published JW/JZ modifier policy, which means mandatory drug wastage reporting applies to this code. Getting this right matters: incorrect modifier use is a common trigger for Medicare audits on chemotherapy claims.

Here is how the two modifiers work in practice.

A common mistake: failing to append either modifier when billing J9264 for Medicare patients. CMS policy requires one of the two on every claim line. Omitting both modifiers may result in denial or a request for documentation during a post-payment audit.

Documentation in the patient record must support whichever modifier is reported. If JW is used, the record should reflect the amount administered and the amount discarded. If JZ is used, the record should confirm the full vial was administered. See patient data security guidance for maintaining compliant treatment records that survive audit scrutiny.

Simplify chemotherapy billing with Pabau

Pabau's claims management tools help oncology billing teams track drug units, apply the right modifiers, and maintain audit-ready documentation for codes like J9264.

Book a demo

Coverage and reimbursement for HCPCS code J9264

J9264 carries a coverage indicator of “C,” which means carrier judgment applies. Medicare does not issue a uniform national coverage determination for this code. Instead, local Medicare Administrative Contractors (MACs) set their own coverage policies based on FDA-approved indications and local coverage determinations (LCDs).

For most oncology practices, this means coverage depends on the submitted diagnosis codes and whether the documented clinical indication aligns with the payer’s LCD. Abraxane holds FDA approval for specific cancer types, and claims should be supported by diagnosis codes that reflect those approved indications. Off-label uses require additional documentation and may face denial without a strong medical necessity narrative.

A covered diagnosis for J9264 generally maps to one of Abraxane’s three FDA-approved indications:

• Metastatic breast cancer after failure of combination chemotherapy, reported with breast neoplasm codes in the C50 family.
• Locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, reported with lung neoplasm codes in the C34 family.
• Metastatic adenocarcinoma of the pancreas, in combination with gemcitabine, reported with pancreatic neoplasm codes in the C25 family.

Commercial payers such as Aetna also recognize a broader set of compendia-supported uses. A claim outside the FDA-approved list needs a medical necessity narrative to survive review, so match the ICD-10 code to what the documentation actually supports.

Medicare Part B covers physician-administered drugs like paclitaxel protein-bound under the buy-and-bill model. The practice purchases the drug, administers it, and bills Medicare for reimbursement.

CMS typically calculates reimbursement at the Average Sales Price (ASP) plus a 6% add-on, though CMS adjusts this percentage periodically and sequestration may reduce it further. J9264 is priced under this ASP methodology rather than the Medicare Physician Fee Schedule, which excludes drug and biological codes like this one.

Because ASP rates update quarterly, confirm current payment amounts against the ASP Drug Pricing Files before each new quarter rather than relying on static figures.

For commercial payers, prior authorization requirements for Abraxane vary significantly by plan and formulary. Some payers require step therapy, meaning the patient must have failed conventional paclitaxel before Abraxane is authorized. Always verify authorization requirements before the infusion date, not after. Supporting prescription management software can help track prior auth status across multiple payers.

NDC codes and crosswalk for J9264

National Drug Code (NDC) reporting is mandatory for HCPCS J-code drug claims under Medicare Part B. The NDC identifies the specific product, manufacturer, and package size dispensed. Report it alongside J9264 on the claim in the qualifier format your billing system requires (typically the 5-4-2 digit format).

Multiple NDC codes crosswalk to HCPCS code J9264, because more than one manufacturer’s nab-paclitaxel product now bills under this code. Bristol-Myers Squibb markets the original Abraxane, acquired through Celgene in 2019, which had itself acquired originator Abraxis BioScience in 2010. American Regent separately markets its own, non-therapeutically-equivalent nab-paclitaxel product.

American Regent’s own J-code, J9259, was discontinued effective January 1, 2025, so that product is now also billed under J9264. Billing teams should confirm the NDC printed on the drug label at the time of dispensing rather than assuming a single manufacturer.

You can find a current NDC-to-HCPCS crosswalk through the AAPC Codify HCPCS lookup or via your MAC’s published crosswalk tables. For comparison, J9190 uses the same per-mg billing structure for a different chemotherapy agent.

Documentation requirements for J9264 claims

Audit-ready documentation for HCPCS code J9264 claims should capture several key elements. Missing any one of them can convert a clean claim into a denial or a recoupment request.

• Diagnosis code(s): ICD-10-CM codes reflecting the approved oncologic indication, linked to the chemotherapy encounter
• Ordered dose: The prescribed dose in mg/m² and the calculated total dose in mg based on the patient’s body surface area
• Administered dose: The actual number of milligrams infused, which becomes the unit count billed on J9264
• Wastage documentation: If the JW modifier is used, the record must reflect the discarded amount and method of disposal
• NDC number: The National Drug Code from the specific vial administered, recorded in the patient encounter note or infusion record
• Lot number and expiration date: Required for product traceability in most oncology settings
• Infusion start and stop times: Needed for any concurrent administration billing (e.g., hydration codes)
• Medical necessity statement: Particularly important for commercial payers and for off-label use scenarios

Product traceability demands like these aren’t unique to oncology. Regenerative medicine practices face similar lot- and NDC-tracking requirements for the biologics they administer.

Using standardized medical forms for chemotherapy documentation helps ensure every required data point is captured consistently across patient encounters. Practices with high infusion volumes benefit from structured intake and encounter forms that prompt clinicians for each required element before the claim is submitted. Pabau’s digital intake forms can be configured to capture these fields at the point of care.

Related HCPCS codes to know alongside J9264

Oncology billing teams coding paclitaxel protein-bound claims will encounter several adjacent codes. Understanding the distinctions prevents cross-coding errors.

The most important distinction is between J9264 (nab-paclitaxel) and J9267 (conventional paclitaxel). These are clinically distinct formulations with different side-effect profiles and dosing schedules. Using the wrong code misrepresents what was administered, not just a billing error. Verify the order and the drug label before selecting the code.

See CMS’s HCPCS Quarterly Update for the full J-code range and any code changes each quarter. You can also compare J9000 for broader oncology billing context.

Two groups of codes come up most often on real J9264 claims. First, the J code for Taxol (conventional paclitaxel) is J9267, and confusing it with J9264 is the single most common cross-coding error.

Second, Abraxane is usually given as part of a combination regimen, so you will frequently bill it alongside the codes for its partner drugs, including J9045 (carboplatin) for non-small cell lung cancer and J9201 (gemcitabine) for pancreatic adenocarcinoma.

ASC versus hospital outpatient billing for J9264

ASCs rarely administer paclitaxel protein-bound; most infusions occur in hospital outpatient departments or physician office settings. Payment methodology differs by setting.

Under the hospital outpatient prospective payment system (HOPPS), a high-cost chemotherapy drug like J9264 is typically assigned status indicator “K,” meaning it is separately payable at ASP+6% under its own Ambulatory Payment Classification (APC) rather than packaged into the infusion service.

Packaging under status indicator “N” is reserved for low-cost drugs that fall below the per-day packaging threshold, which paclitaxel protein-bound does not.

Confirm the current-quarter OPPS Addendum B status indicator for J9264 before billing, since CMS updates these assignments quarterly. Physician office billing (Part B professional claims) also allows separate payment for the drug at ASP+6% alongside the infusion administration codes.

The claim form also changes with the setting. Hospital outpatient departments bill J9264 on a UB-04 (CMS-1450) using drug revenue codes such as 0636 (drugs requiring detailed coding) or 0250 (general pharmacy), while a physician office submits the drug on a CMS-1500 professional claim.

Reporting the drug under the wrong revenue code or form is a frequent cause of packaged-versus-separate payment confusion. Infusion-heavy specialties beyond oncology, including IV therapy practices, face similar site-of-service billing rules, so confirm the setting-specific policy before submitting the claim.

Keeping oncology drug inventory management records accurate is essential when operating across multiple billing settings.

Conclusion

HCPCS code J9264 is a precise, unit-based chemotherapy code with strict modifier, NDC, and documentation requirements. The January 2025 code transition, the mandatory JW/JZ modifier rules, and the carrier-judgment coverage indicator mean billing teams need a reliable, up-to-date workflow to avoid denials and audit exposure.

Pabau gives oncology and infusion practices the tools to track administered units, link NDC codes to claims, and maintain complete encounter documentation for every J-code submission. To see how Pabau handles chemotherapy billing workflows, book a demo with the team.

Continue your research

Billing other injectable procedure codes? Our guide to J7318 covers a different injectable drug’s unit and modifier rules.

Coding a behavioral health visit instead? H0036 explains community psychiatric supportive treatment billing requirements.

Ordering labs to monitor chemotherapy patients? 85025 is the CPT code for an automated CBC with differential.

Frequently asked questions